Details
| Stereochemistry | UNKNOWN |
| Molecular Formula | C17H14O4 |
| Molecular Weight | 282.2907 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C1CCC2=C1C=C(O)C(=C2)C(=O)C3=CC=CC=C3
InChI
InChIKey=XMTKXTUIUKKGIL-UHFFFAOYSA-N
InChI=1S/C17H14O4/c18-15-9-13-11(6-7-12(13)17(20)21)8-14(15)16(19)10-4-2-1-3-5-10/h1-5,8-9,12,18H,6-7H2,(H,20,21)
| Molecular Formula | C17H14O4 |
| Molecular Weight | 282.2907 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Oxindanac, a non-steroidal anti-inflammatory drug, and is a weak cyclooxygenase inhibitor possessed antipyretic activity. This drug is used as a veterinary inflammatory drug. In addition, oxindanac was studied in phase III clinical trials for the treatment of rheumatic disorders. However, this study was discontinued.
Originator
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:14:51 GMT 2023
by
admin
on
Sat Dec 16 10:14:51 GMT 2023
|
| Record UNII |
0K7U57MH88
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
99910-68-6
Created by
admin on Sat Dec 16 10:14:51 GMT 2023 , Edited by admin on Sat Dec 16 10:14:51 GMT 2023
|
PRIMARY | |||
|
0K7U57MH88
Created by
admin on Sat Dec 16 10:14:51 GMT 2023 , Edited by admin on Sat Dec 16 10:14:51 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> ENANTIOMER |
|
||
|
|
RACEMATE -> ENANTIOMER |
